INDEX

Note: Page numbers of article titles are in boldface type.

Acarbose, for diabetic cats, 890
Acromegaly, feline, 1079–1080
  cause of, 1102
  clinical signs of, 1102–1103
  diagnosis of, 1103
  prognosis in, 1103
  treatment of, 1103
Adrenal glands, anatomy of, 1101
  disorders of, in cats, 1075–1079
  pheochromocytoma of, 1102
Anesthesia, for transsphenoidal hypophysectomy, 1028–1029
Antidiuretic hormone, 833–834
  plasma concentrations of, 843
Antidiuretic hormone trial, 842–843
Antithyroid antibodies, 916–919
  prevalence of, in various breeds of dogs, 918
Arginine response test, 852–853
Bisphosphonates, in hypercalcemia, 1052–1053
Calcium, disorders of metabolism of, in cats, 1069
  disorders of regulation of, database survey of, 1055–1058, 1059, 1060
  diagnosis and treatment of, 1043–1062
  specialized assays of, 1044–1047
  ionized, measurement of, in disorders of calcium regulation, 1044–1046
Calcium ipodate, in feline hyperthyroidism, 976
Carcinomas, thyroid, 1096–1097, 1099
Cats, acromegaly in, 1079–1080, 1102–1103
  and dogs, diagnosis of diabetes mellitus in, 845–853
  endocrinology of, update on, 1063–1081
  hyperadrenocorticism in, hypophysectomy as treatment for, 1037–1038
  hyperthyroidism in, 963–983, 1063–1068
Chemotherapy, in insulinoma, 1090
  in thyroid tumors, 1098–1099
Computed tomography, in canine hyperadrenocorticism, 995
  in insulinomas, 1087
Corticotropin, endogenous, measurement of, in canine hyperadrenocorticism, 992
Corticotropin stimulation test, in canine hyperadrenocorticism, 988–989
Cortisol, baseline, measurement of, in canine hyperadrenocorticism, 990–991
Cushing’s disease. See Hyperadrenocorticism.

Dexamethasone suppression/corticotropin stimulation test, in canine hyperadrenocorticism, 989–990
Dexamethasone suppression test, high-dose, in canine hyperadrenocorticism, 991–992
  low-dose, in canine hyperadrenocorticism, 988
Diabetes insipidus, basic defects in, 835
  characteristics of, 834–835
  misdiagnosis of, 841–842
  tests to diagnose, 838–843
  types of, 835–836
  differentiating between, 836, 841
Diabetes mellitus, canine, 845
  aims of therapy for, 858
  classification and pathogenesis of, 855–857
  clinical signs of, 857–858
  dietary recommendations in, 864–867
  diseases concurrent with, 875–876
  home monitoring of blood glucose in, 874–875
  home monitoring of glycemic control in, 868–869

1111
Diabetes mellitus (Continued)
insulin therapy in, 858–863
management of, 855–880
oral hypoglycemic agents in, 863–864
practical routine for owner in, 867–868
serial blood glucose curve and, 869
evaluation of, 870–874
classification of, 881–882
clinical pathologic findings in, 851
feline, 845–846
blood glucose measurements in, 898–899
causes of, 886
diagnosis of, 886–888
feeding in, 895–897
impaired insulin secretion in, 882–884
long-term complications of, 907
management of, 881–913
monitoring of, schedule for, 901–902
monitoring response to therapy in, 897–901
pathogenesis of, 881–886
reduced insulin sensitivity in, 884–885
stabilization of, options for, 888–892
therapeutic options in, 892–895
water consumption assessments in,
899–901
ketoacidotic, hyperosmolar, or complicated, pathophysiology and clinical signs of, 849–851
nonketotic, clinical signs of, 847–848
physical examination findings in, 848–849, 850, 851
type 1, pathogenesis and clinical signs of, 846
type 2, pathogenesis and clinical signs of, 846
Diazoxide, in insulinoma, 1089
Dogs, and cats, diagnosis of diabetes mellitus in, 845–853
diabetes mellitus in, management of, 855–880
hyperadrenocorticism in, diagnosis of, 985–1003
hypophysectomy as treatment for, 1005–1041
medical treatment of, 1005–1014
screening tests in, 986–991, 996–997
signalment, history, and physical examination in, 986
treatment options for, 1013
feline, hypophysectomy as treatment for, 1037–1038
Hyperadrenocorticism, canine, diagnosis of, 985–1003
differentiating tests in, 991–996, 997
hypophysectomy as treatment of, 1015–1041
hypercalcemia, bisphosphonates in, 1052–1053
feline, differential diagnosis of, 1071–1072
idiopathic, and diet, 1069–1071
humoral, of malignancy, 1050
idiopathic, of cats, 1051
ionized calcium and parathyroid hormone assays in, 1049
laboratory abnormalities in, 1047, 1048
parathyroid-dependent, 1047–1049
parathyroid-independent, 1049–1052
Hypergastrinemia, in gastrinoma, 1091–1092
Hyperglycemia, and feline diabetes, 887
stress-induced, 852
Hyperparathyroidism, nutritional secondary, 1074
primary, chemical ablation of parathyroid mass in, 1101
Diabetes mellitus (Continued)
diagnosis of, 1100
Free T4 measurements, in canine hypothyroidism, 955–956
Fructosamine, in diabetes diagnosis, 886–887
Gastrinoma, clinical signs of, 1090–1091
endoscopy in, 1091
hypergastrinemia in, 1091–1092
minimum database in, 1091
physical examination in, 1091
prognosis in, 1093
radiographs in, 1091
surgical treatment of, 1092
Glucagon response test, 852–853
Glucagonoma, 1093–1094
Glucocorticoids, in insulinoma, 1089
Glucose tolerance test, 852–853
Glycosylated proteins, 852
Granulomatous disease, 1052
25-Hydroxyvitamin D, measurement of, in disorders of calcium regulation, 1046–1047
Hyperadrenocorticism, canine, diagnosis of, 985–1003
differentiating tests in, 991–996, 997
hypophysectomy as treatment of, 1015–1041
medical treatment of, 1005–1014
screening tests in, 986–991, 996–997
signalment, history, and physical examination in, 986
treatment options for, 1013
feline, hypophysectomy as treatment for, 1037–1038
Hypercalcemia, bisphosphonates in, 1052–1053
feline, differential diagnosis of, 1071–1072
idiopathic, and diet, 1069–1071
humoral, of malignancy, 1050
idiopathic, of cats, 1051
ionized calcium and parathyroid hormone assays in, 1049
laboratory abnormalities in, 1047, 1048
parathyroid-dependent, 1047–1049
parathyroid-independent, 1049–1052
Hypergastrinemia, in gastrinoma, 1091–1092
Hyperglycemia, and feline diabetes, 887
stress-induced, 852
Hyperparathyroidism, nutritional secondary, 1074
primary, chemical ablation of parathyroid mass in, 1101
diagnosis of, 1100
Diabetes mellitus (Continued)
diagnosis of, 1100
Free T4 measurements, in canine hypothyroidism, 955–956
Fructosamine, in diabetes diagnosis, 886–887
Gastrinoma, clinical signs of, 1090–1091
endoscopy in, 1091
hypergastrinemia in, 1091–1092
minimum database in, 1091
physical examination in, 1091
prognosis in, 1093
radiographs in, 1091
surgical treatment of, 1092
Glucagon response test, 852–853
Glucagonoma, 1093–1094
Glucocorticoids, in insulinoma, 1089
Glucose tolerance test, 852–853
Glycosylated proteins, 852
Granulomatous disease, 1052
25-Hydroxyvitamin D, measurement of, in disorders of calcium regulation, 1046–1047
Hyperadrenocorticism, canine, diagnosis of, 985–1003
differentiating tests in, 991–996, 997
hypophysectomy as treatment of, 1015–1041
medical treatment of, 1005–1014
screening tests in, 986–991, 996–997
signalment, history, and physical examination in, 986
treatment options for, 1013
feline, hypophysectomy as treatment for, 1037–1038
Hypercalcemia, bisphosphonates in, 1052–1053
feline, differential diagnosis of, 1071–1072
idiopathic, and diet, 1069–1071
humoral, of malignancy, 1050
idiopathic, of cats, 1051
ionized calcium and parathyroid hormone assays in, 1049
laboratory abnormalities in, 1047, 1048
parathyroid-dependent, 1047–1049
parathyroid-independent, 1049–1052
Hypergastrinemia, in gastrinoma, 1091–1092
Hyperglycemia, and feline diabetes, 887
stress-induced, 852
Hyperparathyroidism, nutritional secondary, 1074
primary, chemical ablation of parathyroid mass in, 1101
diagnosis of, 1100
Endocrine pancreas, 1083–1094
Endocrine tumors, 1083–1110
Endocrinology, 833–1110
feline, update on, 1063–1081
Ethanol ablation, percutaneous, in feline hyperthyroidism, 979
in cats, 1071
in dogs, 1099
minimum database in, 1100
pathogenesis of, 1099–1100
signs of, 1100
surgical management of, 1100
renal secondary, 1069

Hyperthyroidism, feline, 963–983, 1063–1068
biochemical analyses in, 964–966
clinical presentation of, 1065
definite diagnostic tests in, 966–971
hematologic analyses in, 964
laboratory changes associated with, 1066–1068
pathogenesis of, 1063–1065
screening laboratory tests in, 963–966
therapy of, medical, 971–976
radioactive iodine, 977–978
surgical, 976–977
surgical thyroidectomy in, 976–977
treatment of, 979–980
urinalysis in, 966

Hypervitaminosis D, 1051–1052
Hypoadrenocorticism, 1075–1076
Hypoaldosteronism, primary, 1077–1079
Hypocalcemia, in cats, 1072–1075
laboratory abnormalities in, 1054
parathyroid-dependent, 1053
parathyroid-independent, 1053–1055
Hypoglycemia, in diabetic cats, 906–907
in insulinoma, 1085
Hypoglycemic drugs, oral, for diabetic cats, 888–891
Hypoparathyroidism, primary, in cats, 1072–1074
Hypophysectomy, as treatment for canine hyperadrenocorticism, 1015–1041
as treatment for feline hyperadrenocorticism, 1037–1038
in dog, complications of, 1020
history of, 1015–1017
studies of, 1018–1019
transsphenoidal, microsurgical technique of, 1028–1034
postoperative care in, 1033–1034
results and complications of, 1034–1036
Hypothyroidism, canine, cardiovascular abnormalities in, 943–944
clinical findings in, 936–937
conditions associated with, 935–950
dermatologic abnormalities in, 937–939
diagnosis of, 951–962
endocrine tests to diagnose, 953–954
gastrointestinal abnormalities in, 946
general metabolism in, 937
hematologic abnormalities in, 945–946
myxedema coma in, 946–947
neurologic abnormalities in, 939–942
ocular abnormalities in, 944–945
pathophysiology of, 952
reproductive abnormalities in, 942–943
feline, 1068–1069
suspected, thyroid hormone profiles in, 960–961

Insulin, for diabetic cats, 891–892, 893
in canine diabetes, 858–863
Insulinoma, clinical signs of, 1084–1085
diagnosis of, 1087
hypoglycemia in, 1085
localizing of, 1087
medical management of, 1088–1089
minimum database in, 1085
physical examination in, 1085
prognosis in, 1090
serum insulin concentrations in, 1086
surgical management of, 1088

Ketoacidosis, diabetic, clinicopathologic findings in, 851
in diabetes cats, 887–888

Levodoprenyl, for treatment of hyperadrenocorticism, 1010–1012
Lymphocytic thyroiditis, 915–933
epidemiologic studies of laboratory-based, 927–929
future research directions in, 929–930
heritability of, 921
pathologic and functional stages of, 923–925
preclinical disease associated with, 921–925
progression of, clinical studies of, 925–927

Magnetic resonance imaging, in canine hyperadrenocorticism, 995–996
in insulinomas, 1087
Metformin, for diabetic cats, 890
Mitotane, for treatment of hyperadrenocorticism, 1006–1010
initial induction of, 1006–1007
loading dosage of, 1007–1008
maintenance dosage of, 1008–1010
Multiple endocrine neoplasia, 1094–1095
Myxedema coma, in canine hypothyroidism, 946–947

Obesity, as risk factor for diabetes, 885
Octreotide, in insulinoma, 1089
INDEX

Pancreas, endocrine, 1083–1094
Pancreatitis, following insulinoma surgery, 1088
Parathyroid glands, 1095
tumors of, 1099–1101
Parathyroid hormone, measurement of, in disorders of calcium regulation, 1044
Parathyroid hormone-related protein, measurement of, in disorders of calcium regulation, 1046
Parathyroidectomy, in primary hyperparathyroidism, 1101
Pheochromocytoma, of adrenal glands, 1102
Pituitary gland, anterior, tumors of, 1102–1103
in dogs, pituitary imaging in, 1026–1028
surgical anatomy of, 1017–1026
transsphenoidal approach to, surgical landmarks for, 1023–1026
vascularization of, 1023
Plasma osmolality or plasma sodium, random, tests of, 843
Polydipsia. See Polyuria, and polydipsia.
Polyuria, and polydipsia, 833–844
causes of, 834–836
diagnostic approach to, 836–838
major disorders of, 835

Radioactive iodine, in feline hyperthyroidism, 977–978
Radiography, in canine hyperadrenocorticism, 992–993
in gastrinoma, 1091
Radioisotope uptake, thyroidal, in feline hyperthyroidism, 966
Renal disease, treatment of, 979–980
Rickets, in cats, 1074–1075

Scintigraphy, nuclear, in insulinomas, 1087
Serum alkaline phosphate, measurement of, in canine hyperadrenocorticism, 990–991
Sulfonylurea glipizide, for diabetic cats, 889

T4 replacement therapy, testing in, 959–960
Tapazole, in feline hyperthyroidism, 972
Thiazolidinediones, for diabetic cats, 890–891
Thioureylene antithyroid drugs, in feline hyperthyroidism, 972–976
Thyroglobulin, and thyroid hormone cross-reacting antibodies, in thyroid disease, 918
autoantibodies to, tests to measure, 957–959
Thyroid function tests, dynamic, in feline hyperthyroidism, 969–971
Thyroid gland, 1095
tumors of, 1095–1099
chemotherapy in, 1098
diagnosis of, 1097–1098
minimum database in, 1097
radiation therapy in, 1099
surgical management of, 1098
Thyroid hormones, autoantibodies to, tests to measure, 957–959
circulating concentrations of, assessment of, in feline hyperthyroidism, 966–969
Thyroidectomy, surgical, in feline hyperthyroidism, 976–977
Thyroiditis, autoimmune, heritability of, 920–921
pathogenesis of, 919–920
forms of, 915–916
lymphocytic. See Lymphocytic thyroiditis.
Thyrotropin, canine, assay of, 956–957
Thyrotropin-releasing hormone response tests, 959
Thyrotropin response tests, 959
Total T3 measurements, in canine hypothyroidism, 954–955
Total T4 measurements, in canine hypothyroidism, 953–954

Ultrasonography, abdominal, in canine hyperadrenocorticism, 993–994
and methylene blue, in insulinomas, 1087–1088
Urine cortisol:creatinine ratio, in canine hyperadrenocorticism, 987

Vanadium, for diabetic cats, 889–890

Water balance, physiologic characteristics of, 833–834
Water deprivation test, modified, 838–842
abrupt water deprivation in, 839–840
complications associated with, 842
gradual water restriction in, 839
misdiagnosis associated with, 841–842
response to antidiuretic hormone administration in, 840
urine osmolality versus urine specific gravity in, 838–839

Zollinger-Ellison syndrome. See Gastrinoma.